Alnylam ALN-APP-001: Phase I, placebo-controlled trial of ALN-APP in participants with Early-Onset Alzheimer’s disease
J
Jared Brosch, MD
Primary Investigator
Recruiting
18-100 years
All
Phase
1
4 participants needed
3 Locations
Brief description of study
Who is Eligible
- Ages 18+
- Must have had symptoms of Alzheimer’s disease prior to age 65
- Diagnosis of Alzheimer’s disease
- Must be able to complete MRI
- Must be able to tolerate lumbar puncture
- No history of seizures, stroke or cancer in the last 5 years
What is Involved
- In-person visits at IUH Neuroscience Center and University Hospital
- Participants will receive at least one dose of medication injected by a physician into their spinal canal with local anesthesia. Participants will stay overnight at University Hospital directly following the first injection of medication.
- Participation will last 6 months to 12 months following administration, for blood work and imaging analysis
Compensation
- Compensation available via payment card for each completed appointment
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alzheimer’s disease
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 14597
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
